1. Home
  2. GFAI vs RNTX Comparison

GFAI vs RNTX Comparison

Compare GFAI & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GFAI
  • RNTX
  • Stock Information
  • Founded
  • GFAI 2018
  • RNTX 2001
  • Country
  • GFAI Singapore
  • RNTX United States
  • Employees
  • GFAI N/A
  • RNTX N/A
  • Industry
  • GFAI Diversified Commercial Services
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • GFAI Consumer Discretionary
  • RNTX Health Care
  • Exchange
  • GFAI Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • GFAI 23.5M
  • RNTX 28.0M
  • IPO Year
  • GFAI N/A
  • RNTX N/A
  • Fundamental
  • Price
  • GFAI $1.13
  • RNTX $1.15
  • Analyst Decision
  • GFAI Strong Buy
  • RNTX Hold
  • Analyst Count
  • GFAI 1
  • RNTX 1
  • Target Price
  • GFAI $4.50
  • RNTX N/A
  • AVG Volume (30 Days)
  • GFAI 517.0K
  • RNTX 133.3K
  • Earning Date
  • GFAI 09-25-2025
  • RNTX 11-13-2025
  • Dividend Yield
  • GFAI N/A
  • RNTX N/A
  • EPS Growth
  • GFAI N/A
  • RNTX N/A
  • EPS
  • GFAI N/A
  • RNTX N/A
  • Revenue
  • GFAI $36,347,373.00
  • RNTX N/A
  • Revenue This Year
  • GFAI $5.66
  • RNTX N/A
  • Revenue Next Year
  • GFAI $4.69
  • RNTX N/A
  • P/E Ratio
  • GFAI N/A
  • RNTX N/A
  • Revenue Growth
  • GFAI 0.18
  • RNTX N/A
  • 52 Week Low
  • GFAI $0.76
  • RNTX $1.04
  • 52 Week High
  • GFAI $3.88
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • GFAI 48.74
  • RNTX 45.62
  • Support Level
  • GFAI $1.04
  • RNTX $1.07
  • Resistance Level
  • GFAI $1.11
  • RNTX $1.25
  • Average True Range (ATR)
  • GFAI 0.06
  • RNTX 0.14
  • MACD
  • GFAI 0.01
  • RNTX -0.01
  • Stochastic Oscillator
  • GFAI 50.28
  • RNTX 21.33

About GFAI Guardforce AI Co. Limited

Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, General Security Solutions, and Corporate and others. A majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: